Effect Of Injection Of Recombinant Activated Factor VII On The Postoperative Recovery In Patients Undergoing Cardiac Surgery

Objective: To test the hypothesis that recombinant factor VIIa(rFVIIa) could reduce postoperative blood loss and improve the function of blood coagulation in patients undergoing valve replacement surgery requiring cardiopulmonary bypass (CPB). Methods: In a double-blind placebo-controlled randomized trial, 22 patients were randomized to receive an intravenous bolus of recombinant factor VIIa (40μg/kg) or placebo after CPB and reversal of heparin. We assessed and compared the blood loss, use of blood products, coagulation indicators, blood regulate test, length of stay, and cost of hospitalization, et al. Results: There were no thrombotic complications, no cardiac ischemic events, and no deaths. The amount of postoperative blood loss and the need for transfusion and the parameter of blood coagulation such as INR and PT reduced conspicuously in patients who had used rFVIIa. Conclusion: These results suggest that an injection of rFVIIa can reduce postoperative blood loss and the need for allogeneic transfusion and can improve the function of blood coagulation in patients without causing thromboembolic complications.